A subsequent phase 2 study was planned on the basis of this promising data: INTELLANCE 2/EORTC1410 (NCT02343406) was a multicenter, randomized open label study comparing Depatux-M plus TMZ (arm 1) versus Depatux-M alone (arm 2) versus standard treatment of TMZ/lomustine (arm 3/control arm) in EGFR-amplified GBM at first recurrence/progression after standard chemoradiotherapy [16]. This evidence concerns the gene EGFR and glioblastoma.